Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575108 | 0.88 | HDAC1 (0.55) | HDAC1NPSR1CASP3CASP2 | |
| SCHEMBL13036451 | 0.84 | HDAC1 (0.49) | HDAC1NPSR1CASP3CASP2F10 | |
| SCHEMBL3566096 | 0.82 | HDAC1 (0.49) | HDAC1NPSR1CASP3CASP2PIN1 | |
| SCHEMBL3572716 | 0.81 | HDAC1 (0.56) | HDAC1NPSR1CASP3CASP2NPC1 | |
| SCHEMBL8350853 | 0.81 | HDAC1 (0.58) | HDAC1NPC1RAB9APIN1F10 | |
| SCHEMBL3569339 | 0.77 | HDAC1 (0.74) | HDAC1 | |
| SCHEMBL3562084 | 0.76 | HDAC1 (0.62) | HDAC1 | |
| SCHEMBL3565271 | 0.76 | MEN1 (0.54) | HDAC1NPSR1CASP2ALDH1A1HTT | |
| SCHEMBL3581315 | 0.74 | HDAC1 (0.55) | HDAC1 | |
| SCHEMBL1893680 | 0.74 | HDAC1 (1.00) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | HDAC1 4/4885NPSR1 3405/4885CASP3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.